Detailed Information

Cited 3 time in webofscience Cited 3 time in scopus
Metadata Downloads

Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity score-matched study using the Korean Renal Cancer Study Group database

Authors
Lee, Chan HoChung, JinsooKwak, CheolJeong, Chang WookSeo, Seong IlKang, MinyongHong, Sung-HooSong, CherynPark, Jae YoungHwang, Eu ChangLee, HakminKu, Ja YoonSeo, Won IkChoi, Seock HwanHa, Hong KooKorean Renal Cancer Study Group
Issue Date
Apr-2021
Publisher
WILEY
Keywords
late recurrence; prognosis; renal cell carcinoma; targeted therapy
Citation
INTERNATIONAL JOURNAL OF UROLOGY, v.28, no.4, pp 417 - 423
Pages
7
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF UROLOGY
Volume
28
Number
4
Start Page
417
End Page
423
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/52191
DOI
10.1111/iju.14485
ISSN
0919-8172
1442-2042
Abstract
Objectives: To investigate the clinicopathological features and outcomes of targeted therapy in patients with recurrence of renal cell carcinoma in < 5 years or >= 5 years after the surgical treatment for renal cell carcinoma. Methods: Patients with metastatic renal cell carcinoma treated with targeted therapy in a multicenter database were retrospectively characterized according to time from surgery to recurrence. Early recurrence was defined as recurrence within 5 years after surgery, and late recurrence was defined as occurring >= 5 years after surgery. The propensity scores for recurrence status were calculated, and patients with late recurrence were matched to patients with early recurrence at a 1:3 ratio. The oncological outcomes of targeted therapy in both groups were compared. Results: Among 716 patients, 512 (71.5%) experienced early recurrence and 204 (28.5%) experienced late recurrence. The patients with late recurrence presented with younger age at surgery, lower tumor stages and Fuhrman grade, and fewer sarcomatoid features and lymphovascular invasion (all P < 0.005). All differences in clinicopathological characteristics before targeted therapy disappeared after matching. Patients with late recurrence had significantly longer median overall survival (56 months vs 36 months; P < 0.0001) and median first-line progression-free survival (12 months vs 8 months; P = 0.031). The early recurrence status was a significantly worse predictor for overall survival and first-line progression-free survival (hazard ratio 1.30, P = 0.007; and hazard ratio 1.76, P < 0.001, respectively). Conclusions: Late recurrence might have prognostic value in terms of oncological outcomes in metastatic renal cell carcinoma treated with targeted therapy.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Jae Young photo

Park, Jae Young
Ansan Hospital (Department of Urology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE